BioMarin Announces Program For BMN-111 For The Treatment Of Achondroplasia

Links shared publicly online about this topic.

787
total visits

BioMarin Announces Program For BMN-111 For The Treatment Of Achondroplasia

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 20

View full resource at medicalnewstoday.com

Tags: Pharma

Most Recently Shared on October 21, 2010 at 1:05 am By:

MNT Genetics News

BioMarin Announces Program For BMN-111 For The Treatment Of Achondroplasia http://mnt.to/3Ltc #genetics

2 years ago...

Retweet

Favorite

Also Shared By:

BioMarin announces BMN-111 program for treatment of achondroplasia

news-medical.net — “BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.” View full resource at news-medical.net